Sarah Sheibani1,2, Russell Cohen3, Sunanda Kane4, Marla Dubinsky5, Joseph A Church6, Uma Mahadevan7. 1. Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. sarah.sheibani@usc.edu. 2. Division of Gastroenterology, University of Southern California, Keck School of Medicine, 1520 San Pablo Street, Suite 1000, Los Angeles, CA, 90033-5312, USA. sarah.sheibani@usc.edu. 3. Division of Gastroenterology, Department of Medicine, University of Chicago, Chicago, IL, USA. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 5. Division of Gastroenterology, Department of Medicine, Mt. Sinai Medical Center, New York, NY, USA. 6. Division of Clinical Immunology and Allergy, Department of Pediatrics, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 7. Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Infliximab (IFX) and adalimumab (ADA) cross the placenta in the third trimester and can be detectable in infants for up to 12 months. AIM: The aim of this study was to determine whether in utero IFX or ADA exposure results in an impaired immune response in infants, as measured by immunoglobulin levels and antibody responses to routine primary immunizations. METHODS: Infants who were exposed to in utero anti-TNFα agents were prospectively evaluated. Immunoglobulin levels (IgG, IgM, IgA) and antibodies to standard vaccinations, including tetanus toxoid (tetanus) and Haemophilus influenza type b (Hib), were measured in infants of at least 6 months of age. RESULTS: Twelve infants were prospectively studied: 10 exposed to in utero IFX and 2 exposed to ADA with at least one dose administered in the third trimester. Immunoglobulin levels were available on 10/12 patients, with all showing adequate immunoglobulin levels, except for low IgM levels in 5 (50 %) infants. Adequate responses to both the tetanus and Hib vaccines were seen in 11 of 12 (92 %) infants. CONCLUSIONS: Infants exposed to anti-TNFα agents in utero demonstrate appropriate response to two commonly administered neonatal vaccines and show adequate immunoglobulin levels, except for IgM. Newborns with a history of exposure to anti-TNFα agents should follow a standard vaccination schedule for inactive vaccines.
BACKGROUND:Infliximab (IFX) and adalimumab (ADA) cross the placenta in the third trimester and can be detectable in infants for up to 12 months. AIM: The aim of this study was to determine whether in utero IFX or ADA exposure results in an impaired immune response in infants, as measured by immunoglobulin levels and antibody responses to routine primary immunizations. METHODS:Infants who were exposed to in utero anti-TNFα agents were prospectively evaluated. Immunoglobulin levels (IgG, IgM, IgA) and antibodies to standard vaccinations, including tetanus toxoid (tetanus) and Haemophilus influenza type b (Hib), were measured in infants of at least 6 months of age. RESULTS: Twelve infants were prospectively studied: 10 exposed to in utero IFX and 2 exposed to ADA with at least one dose administered in the third trimester. Immunoglobulin levels were available on 10/12 patients, with all showing adequate immunoglobulin levels, except for low IgM levels in 5 (50 %) infants. Adequate responses to both the tetanus and Hib vaccines were seen in 11 of 12 (92 %) infants. CONCLUSIONS:Infants exposed to anti-TNFα agents in utero demonstrate appropriate response to two commonly administered neonatal vaccines and show adequate immunoglobulin levels, except for IgM. Newborns with a history of exposure to anti-TNFα agents should follow a standard vaccination schedule for inactive vaccines.
Authors: M J Casanova; M Chaparro; E Domènech; M Barreiro-de Acosta; F Bermejo; E Iglesias; F Gomollón; L Rodrigo; X Calvet; M Esteve; E García-Planella; S García-López; C Taxonera; M Calvo; M López; D Ginard; M Gómez-García; E Garrido; J L Pérez-Calle; B Beltrán; M Piqueras; C Saro; B Botella; C Dueñas; A Ponferrada; M Mañosa; V García-Sánchez; J Maté; J P Gisbert Journal: Am J Gastroenterol Date: 2013-01-15 Impact factor: 10.864
Authors: Z Zelinkova; C de Haar; L de Ridder; M J Pierik; E J Kuipers; M P Peppelenbosch; C J van der Woude Journal: Aliment Pharmacol Ther Date: 2011-03-01 Impact factor: 8.171
Authors: Uma Mahadevan; Salvatore Cucchiara; Jeffrey S Hyams; Flavio Steinwurz; F Nuti; Simon P L Travis; William J Sandborn; Jean-Frederio Colombel Journal: Am J Gastroenterol Date: 2010-12-14 Impact factor: 10.864
Authors: Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein Journal: Am J Gastroenterol Date: 2004-12 Impact factor: 10.864
Authors: Bente Nørgård; Heidi H Hundborg; Bent A Jacobsen; Gunnar L Nielsen; Kirsten Fonager Journal: Am J Gastroenterol Date: 2007-06-15 Impact factor: 10.864
Authors: Dawn B Beaulieu; Ashwin N Ananthakrishnan; Christopher Martin; Russell D Cohen; Sunanda V Kane; Uma Mahadevan Journal: Clin Gastroenterol Hepatol Date: 2017-09-01 Impact factor: 11.382
Authors: Ko Eun Lee; Sung-Ae Jung; Sang Hyoung Park; Chang Mo Moon; So Yeon Shim; Eun Soo Kim; Su Jin Cho; Seong-Eun Kim; Kwang Bum Cho; Suk-Kyun Yang Journal: Intest Res Date: 2019-02-08
Authors: Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade Journal: J Cutan Med Surg Date: 2018-11-21 Impact factor: 2.092
Authors: Ana Esteve-Solé; Àngela Deyà-Martínez; Irene Teixidó; Elena Ricart; Macarena Gompertz; Maria Torradeflot; Noemí de Moner; Europa Azucena Gonzalez; Ana Maria Plaza-Martin; Jordi Yagüe; Manel Juan; Laia Alsina Journal: Front Immunol Date: 2017-09-21 Impact factor: 7.561